Irsogladine maleate potentiates the effects of nitric oxide on activation of cAMP signalling pathways and suppression of mesangial cell mitogenesis

British Journal of Pharmacology

Volumn 151, Issue 4, 2007, Pages 457-466

  Yao, J ^a   Zhu, Y ^a   Sun, W ^b   Sawada, N ^a   Hiramatsu, N ^a   Takeda, M ^a   Kitamura, M ^a  

^a UNIVERSITY OF YAMANASHI   (Japan)

^b NANJING UNIVERSITY OF CHINESE MEDICINE   (China)

Author keywords

cAMP; cAMP response element; Connexin43; Irsogladine maleate; Mesangial cell; Nitric oxide; Phosphodiesterase; Proliferation

Indexed keywords

4 AMINO 5 CYCLOPROPYL 2 [1 (2 FLUOROBENZYL) 1H PYRAZOLO[3,4 B]PYRIDIN 3 YL]PYRIMIDINE; 8 BROMO CYCLIC GMP; CILOSTAMIDE; CYCLIC AMP; CYTOKINE; GAP JUNCTION PROTEIN; INDUCIBLE NITRIC OXIDE SYNTHASE; IRSOGLADINE MALEATE; MITOGEN ACTIVATED PROTEIN KINASE; N ACETYL S NITROSOPENICILLAMINE; NITRIC OXIDE; NITRIC OXIDE DONOR; PHOSPHODIESTERASE III; PHOSPHODIESTERASE III INHIBITOR; PHOSPHODIESTERASE IV INHIBITOR; ROLIPRAM; VASODILATOR STIMULATED PHOSPHOPROTEIN;

ANIMAL CELL; ANIMAL EXPERIMENT; ARTICLE; CELL PROLIFERATION; CONTROLLED STUDY; DRUG EFFECT; DRUG POTENTIATION; ENZYME ACTIVATION; GLOMERULUS; MALE; MESANGIUM CELL; MITOGENESIS; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; RAT;

3',5'-CYCLIC-NUCLEOTIDE PHOSPHODIESTERASE; ANIMALS; ANTI-ULCER AGENTS; CELL PROLIFERATION; CONNEXIN 43; CYCLIC AMP; DRUG SYNERGISM; MALE; MESANGIAL CELLS; NITRIC OXIDE; NITRIC OXIDE DONORS; NITRIC OXIDE SYNTHASE TYPE II; PENICILLAMINE; RATS; RATS, SPRAGUE-DAWLEY; SIGNAL TRANSDUCTION; TRIAZINES;

EID: 34250322705     PISSN: 00071188     EISSN: 14765381     Source Type: Journal    
DOI: 10.1038/sj.bjp.0707255     Document Type: Article

References (40)

1. Aizawa T, Wei H, Miano JM, Abe JI, Berk BC, Yan C (2003). Role of phosphodiesterase 3 in NO/cGMP-mediated antiinflammatory effects in vascular smooth muscle cells. Circ Res 93: 406-413.
2. Beavo JA (1995). Cyclic nucleotide phosphodiesterases: functional implications of multiple isoforms. Physiol Rev 75: 725-748.
3. Cheng J, Thompson MA, Walker HJ, Gray CE, Diaz Encarnacion MM, Warner GM et al. (2004). Differential regulation of mesangial cell mitogenesis by cAMP phosphodiesterase isozymes 3 and 4. Am J Physiol Renal Physiol 287: F940-F953.
4. Choudhury GG, Biswas P, Grandalliano G, Fouqueray B, Harvey SA, Abboud HE (1994). PDGF-mediated activation of phosphatidylinositol 3 kinase in human mesangial cells. Kidney Int 46: 37-47.
5. Craven PA, Studer RK, Felder J, Phillips S, DeRubertis FR (1997). Nitric oxide inhibition of transforming growth factor-beta and collagen synthesis in mesangial cells. Diabetes 46: 671-681.
6. Dousa TP (1999). Cyclic-3′,5′-nucleotide phosphodiesterase isozymes in cell biology and pathophysiology of the kidney. Kidney Int 55: 29-62.
7. Garg UC, Hassid A (1989). Inhibition of rat mesangial cell mitogenesis by nitric oxide-generating vasodilators. Am J Physiol 257: F60-F66.
8. Goodenough DA, Goliger JA, Paul DL (1996). Connexins, connexons, and intercellular communication. Annu Rev Biochem 65: 475-502.
9. 15N]nitrate in biological fluids. Anal Biochem 126: 131-138.
10. Ibarra-Alvarado C, Galle J, Melichar VO, Mameghani A, Schmidt HH (2002). Phosphorylation of blood vessel vasodilator-stimulated phosphoprotein at serine 239 as a functional biochemical marker of endothelial nitric oxide/cyclic GMP signaling. Mol Pharmacol 61: 312-319.
11. Ishizuka S, Cunard R, Poucell-Hatton S, Wead L, Lortie M, Thomson SC et al. (2000). Agmatine inhibits cell proliferation and improves renal function in anti-thy-1 glomerulonephritis. J Am Soc Nephrol 11: 2256-2264.
12. Iwata F, Joh T, Ueda F, Yokoyama Y, Itoh M (1998). Role of gap junctions in inhibiting ischemia-reperfusion injury of rat gastric mucosa. Am J Physiol 275: G883-G888.
13. Jover B, Mimran A (2001). Nitric oxide inhibition and renal alterations. J Cardiovasc Pharmacol 38 (Suppl 2): S65-S70.
14. Kang DH, Nakagawa T, Feng L, Johnson RJ (2002). Nitric oxide modulates vascular disease in the remnant kidney model. Am J Pathol 161: 239-248.
15. Kawasaki Y, Tsuchida A, Sasaki T, Yamasaki S, Kuwada Y, Murakami M et al. (2002). Irsogladine malate up-regulates gap junctional intercellular communication between pancreatic cancer cells via PKA pathway. Pancreas 25: 373-377.
16. Kitamura M, Taylor S, Unwin R, Burton S, Shimizu F, Fine LG (1994). Gene transfer into the rat renal glomerulus via a mesangial cell vector: site-specific delivery, in situ amplification, and sustained expression of an exogenous gene in vivo. J Clin Invest 94: 497-505.
17. Klahr S, Morrissey J (2004). L-arginine as a therapeutic tool in kidney disease. Semin Nephrol 24: 389-394.
18. Kumar NM, Gilula NB (1996). The gap junction communication channel. Cell 84: 381-388.
19. Kyoi T, Noda K, Oka M, Ukai Y (2004a). Irsogladine, an anti-ulcer drug, suppresses superoxide production by inhibiting phosphodiesterase type 4 in human neutrophils. Life Sci 76: 71-83.
20. Kyoi T, Oka M, Noda K, Ukai Y (2003). Irsogladine prevents monochloramine-induced gastric mucosal lesions by improving the decrease in mucosal blood flow due to the disturbance of nitric oxide synthesis in rats. J Pharmacol Sci 93: 314-320.
21. Kyoi T, Oka M, Noda K, Ukai Y (2004b). Phosphodiesterase inhibition by a gastroprotective agent irsogladine: preferential blockade of cAMP hydrolysis. Life Sci 75: 1833-1842.
22. Matousovic K, Grande JP, Chini CC, Chini EN, Dousa TP (1995). Inhibitors of cyclic nucleotide phosphodiesterase isozymes type-III and type-IV suppress mitogenesis of rat mesangial cells. J Clin Invest 96: 401-410.
23. Muhl H, Pfeilschifter J (1995). Amplification of nitric oxide synthase expression by nitric oxide in interleukin 1 beta-stimulated rat mesangial cells. J Clin Invest 95: 1941-1946.
24. Muhl H, Sandau K, Brune B, Briner VA, Pfeilschifter J (1996). Nitric oxide donors induce apoptosis in glomerular mesangial cells, epithelial cells and endothelial cells. Eur J Pharmacol 317: 137-149.
25. Nakashima Y, Kohno H ON EL-A, Dhar DK, Ueda F, Nagasue N (2000). Irsogladine upregulates expressions of connexin32 and connexin26 in the rat liver. Hepatol Res 18: 29-42.
26. Narita I, Border WA, Ketteler M, Noble NA (1995). Nitric oxide mediates immunologic injury to kidney mesangium in experimental glomerulonephritis. Lab Invest 72: 17-24.
27. Noris M, Remuzzi G (1999). Physiology and pathophysiology of nitric oxide in chronic renal disease. Proc Assoc Am Physicians 111: 602-610.
28. Oelze M, Mollnau H, Hoffmann N, Warnholtz A, Bodenschatz M, Smolenski A et al. (2000). Vasodilator-stimulated phosphoprotein serine 239 phosphorylation as a sensitive monitor of defective nitric oxide/cGMP signaling and endothelial dysfunction. Circ Res 87: 999-1005.
29. Osinski MT, Rauch BH, Schror K (2001). Antimitogenic actions of organic nitrates are potentiated by sildenafil and mediated via activation of protein kinase A. Mol Pharmacol 59: 1044-1050.
30. Rupprecht HD, Akagi Y, Keil A, Hofer G (2000). Nitric oxide inhibits growth of glomerular mesangial cells: role of the transcription factor EGR-1. Kidney Int 57: 70-82.
31. Shultz PJ, DiCorleto PE, Silver BJ, Abboud HE (1988). Mesangial cells express PDGF mRNAs and proliferate in response to PDGF. Am J Physiol 255: F674-F684.
32. Takahashi N, Joh T, Yokoyama Y, Seno K, Nomura T, Ohara H et al. (2000). Importance of gap junction in gastric mucosal restitution from acid-induced injury. J Lab Clin Med 136: 93-99.
33. Uchida Y, Shiba H, Komatsuzawa H, Hirono C, Ashikaga A, Fujita T et al. (2005). Irsogladine maleate influences the response of gap junctional intercellular communication and IL-8 of human gingival epithelial cells following periodontopathogenic bacterial challenge. Biochem Biophys Res Commun 333: 502-507.
34. Wang Y, Kramer S, Loof T, Martini S, Kron S, Kawachi H et al. (2005). Stimulation of soluble guanylate cyclase slows progression in anti-thy1-induced chronic glomerulosclerosis. Kidney Int 68: 47-61.
35. Yamamoto H, Umeda M, Mizoguchi H, Kato S, Takeuchi K (1999). Protective effect of irsogladine on monochloramine induced gastric mucosal lesions in rats: a comparative study with rebamipide. World J Gastroenterol 5: 477-482.
36. Yao J, Hiramatsu N, Zhu Y, Morioka T, Takeda M, Oite T et al. (2005). Nitric oxide-mediated regulation of connexin43 expression and gap junctional intercellular communication in mesangial cells. J Am Soc Nephrol 16: 58-67.
37. Yao J, Kitamura M, Zhu Y, Meng Y, Kasai A, Hiramatsu N et al. (2006). Synergistic effects of PDGF-BB and cAMP-elevating agents on expression of connexin43 in mesangial cells. Am J Physiol Renal Physiol 290: F1083-F1093.
38. Yao J, Morioka T, Oite T (2000). PDGF regulates gap junction communication and connexin43 phosphorylation by PI 3-kinase in mesangial cells. Kidney Int 57: 1915-1926.
39. Yao J, Schoecklmann HO, Prols F, Gauer S, Sterzel RB (1998). Exogenous nitric oxide inhibits mesangial cell adhesion to extracellular matrix components. Kidney Int 53: 598-608.
40. Zhu Y, Yao J, Meng Y, Kasai A, Hiramatsu N, Hayakawa K et al. (2006). Profiling of functional phosphodiesterase in mesangial cells using a CRE-SEAP-based reporting system. Br J Pharmacol 148: 833-844.